Previous Article | Next Article 
Journal of Virology, March 2000, p. 2900-2902, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Superantigen Expression Is Driven by Both Mouse
Mammary Tumor Virus Long Terminal Repeat-Associated Promoters in
Transgenic Mice
Brian
Salmons,1
Thomas
Miethke,2
Stefan
Wintersperger,3
Mathias
Müller,4
Gottfried
Brem,4 and
Walter H.
Günzburg3,5,*
Bavarian Nordic, D-82152
Martinsried,1 Institute for Microbiology
and Hygiene, Technical University, D-80539
Munich,2 and Institute of Molecular
Virology, GSF-Neuherberg, D-85758
Oberschleissheim,3 Germany, and
Institute of Animal Breeding and
Genetics4 and Institute of
Virology,5 University of Veterinary
Sciences, A-1210 Vienna, Austria
Received 9 November 1999/Accepted 15 December 1999
 |
ABSTRACT |
In addition to the usual retroviral promoter, the mouse mammary
tumor virus (MMTV) long terminal repeat carries a second promoter located in the U3 region. Here we show that both of these promoters are
independently able to give rise to superantigen activity in transgenic
mice. The ability of multiple MMTV promoters to drive superantigen
expression underscores its importance in the virus life cycle.
 |
TEXT |
The long terminal repeat (LTR) of
mouse mammary tumor virus (MMTV) encodes a superantigen (Sag). After
infection of mice with exogenous virus, expression of Sag in
antigen-presenting cells, such as B lymphocytes, specifically
stimulates the proliferation of whole classes of T cells bearing the
cognate V
chain as part of their T-cell receptor (1).
This T-cell stimulation results in local cytokine production and, in
turn, proliferation of B cells in the vicinity, including those that
were infected with MMTV. The virus thus uses the host immune system to
establish and amplify a reservoir of infected cells. Later, the virus
is passed to mammary epithelial cells by an as-yet-unknown mechanism and causes mammary tumors in susceptible mice (12).
Expression of Sag from endogenous, germ line-transmitted MMTVs leads to
deletion and/or anergy of specific reactive V
-bearing classes of T
cells (1). The deletion thereby protects mice from
subsequent challenge with an MMTV encoding a Sag with the same V
specificity (4).
MMTV is unusual among retroviruses in that it carries, in addition to
the classic retroviral promoter (P1196), a second promoter (P698) (Fig. 1) (8, 16,
17). Intriguingly, both of these promoters independently give
rise to Sag activity in mixed-lymphocyte reactions when coupled 5' to a
Sag encoding the 3' LTR (16, 17). To determine which of the
two LTR-associated promoters is used in vivo for Sag expression, a
number of transgenic mouse lines carrying the coding region for the Sag
of the Mtv-2 provirus linked to either P1196,
P698, or both promoters were established. Construction of
the plasmids pORFexp, p
U3, and p
RU5 has been previously described
(17). The inserts containing the miniproviruses were excised
from each plasmid and used for microinjection into freshly isolated
C57BL/B6 mouse oocytes. These were reimplanted after 12 h of
cultivation into recipient pseudopregnant NMRI mice as previously
described (3). DNA was prepared from tail clips of
6-week-old offspring and analyzed by PCR using the previously described
primers located at +702 or +1211 together with primer
1730
(8) or a new primer,
3302 (5'-GCAACTTCCCCCAATAGCC-3') (Fig. 1). Since all mice carry endogenous MMTV copies, signals specific for the deleted miniproviruses were indicative of
transgenicity. Mice transgenic for p
RU5 gave an indicative 0.5-kb
fragment with the primers +702 and
1730 as the result of the deletion
of the R and U5 sequences. Both the pORFexp and the p
U3 mice gave an indicative 2.1-kb fragment with the primers +1211 and
3302 as the
result of the deletion of the pol and env
sequences (data not shown).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of the MMTV constructs used.
The plasmid pGR102 carries a hybrid provirus in which the 5' half is
from Mtv-8 and the 3' half is from Mtv-2 (13). The Sag,
encoded by the open reading frame located in the 3' LTR (shaded box),
is thus derived from the Mtv-2 provirus and specifically interacts with
V 14-bearing T cells (2). The plasmid pORFexp was derived
from pGR102 by deletion of the internal NcoI fragment. Also
shown are the locations of the classic promoter (P1196) and
other promoters present in the LTR (P698) or in the
env gene (P7246 and P8498)
(nomenclature as given in reference 11). The
enhancer (Epol) shown to be important for Sag activity from
P7246 is indicated as an open box, as are the
HpaI (H), PvuII (P), and NcoI (N)
restriction sites used in the construction of the plasmids pORFexp,
p U3, and p RU5. At the bottom of the figure, the positions of the
primers used for the PCR analysis are shown.
|
|
Expression of the Mtv-2 Sag results in the deletion or anergy of
V
14-bearing T cells (8). After 100 µl of blood from the retro bulbar plexus of anesthetized transgenic mice was sampled using a
glass capillary, the T cells were stained with R-phycoerythrin-labeled anti-CD3 monoclonal antibody and a fluorescein-conjugated anti-V
14 monoclonal antibody and analyzed by flow cytofluorometry
(fluorescence-activated cell sorting) (Elite Coulter Inc.) to determine
the percentage of V
14+ T cells. Table
1 shows that these T cells were deleted
(between <1 and 1.4%) in mice regardless of the promoter carried by
the construct but that this deletion did not occur in nontransgenic mice (8.3%). Thus, both LTR-associated promoters have the potential to
give rise to Sag activity in vivo in the temporal window during ontogeny, allowing deletion of V
14-bearing T cells. Additionally, these results show that both promoters are active in the
antigen-presenting cells involved in the establishment of Sag-mediated
tolerance. These data are consistent with previous data obtained with a
mixed-lymphocyte reaction in vitro (17) in that the p
RU5
construct, which carries only the new P698 promoter, shows
the best Sag activity. Although we cannot rule out the possibility that
the sequences deleted in our constructs normally silence one promoter
or the other, this seems unlikely, since transcripts from both
promoters can be detected in B cells (and mammary tumor GR cells)
carrying the Mtv-2 locus (8).
Evidence has been presented that a promoter located within the
env coding sequences (P7246) (10, 15,
18), in association with an enhancer element located in the pol
region (Epol), directs between 98 and 99.7% of Sag gene
expression in B cells (11). However, these elements are not
included in the constructs described here (Fig. 1). There is an
additional promoter (P8498) in our construct; however, only
low-level expression (0.3% maximum) has been attributed to this
promoter (11). Thus, taken together, our data suggest that,
in the absence of the P7246 promoter, either of the LTR
promoters can also drive expression of a functional Sag in vivo, during
ontogeny. We have previously shown the presence of spliced messages
from these promoters to the Sag open reading frame (8, 9).
The presence of multiple promoters in MMTV may act as a fail-safe
feature, ensuring Sag expression. Such Sag expression from endogenous
MMTVs protects mice against infection with exogenous virus since the
cognate T-cell classes are deleted (4), whereas the use of
redundant promoters in exogenous viruses may ensure establishment of
infection. Further, transcripts from the P698 promoter in
particular may be important for the generation of new MMTV variants, in
order to overcome infection restrictions imposed by the Sag-mediated
T-cell deletion (14). Such MMTV variants arising from
recombinations between pre-existing endogenous and exogenous viruses
have been recently detected (5-7).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institute of
Virology, University of Veterinary Sciences, Josef-Baumann-Gasse 1, A-1210 Vienna, Austria. Phone: 43-1-25077-2301. Fax: 43-1-25077-2390. E-mail: walter.guenzburg{at}vu-wien.ac.at.
 |
REFERENCES |
| 1.
|
Acha-Orbea, H., and H. R. MacDonald.
1995.
Superantigens of mouse mammary tumor virus.
Annu. Rev. Immunol.
13:459-486[CrossRef][Medline].
|
| 2.
|
Acha-Orbea, H.,
A. N. Shakov,
L. Scarpellino,
E. Kolb,
V. Muller,
A. Vessaz-Shaw,
R. Fuchs,
K. Blochlinger,
P. Rollini,
J. Billotte,
M. Sarafidou,
H. R. MacDonald, and H. Diggelmann.
1991.
Clonal deletion of V 14-bearing T cells in mice transgenic for mammary tumour virus.
Nature
350:207-211[CrossRef][Medline].
|
| 3.
|
Brem, G.
1998.
Transgene nutztiere.
Zuchtungskunde
60:248-262.
|
| 4.
|
Golovkina, T. V.,
A. Chervonsky,
J. P. Dudley, and S. R. Ross.
1992.
Transgenic mouse mammary tumor virus superantigen expression prevents viral infection.
Cell
69:637-645[CrossRef][Medline].
|
| 5.
|
Golovkina, T. V.,
A. B. Jaffe, and S. R. Ross.
1994.
Co-expression of exogenous and endogenous mouse mammary tumor virus RNA in vivo results in viral recombination and broadens the virus host range.
J. Virol.
68:5019-5026[Abstract/Free Full Text].
|
| 6.
|
Golovkina, T. V.,
O. Prakash, and S. R. Ross.
1996.
Endogenous mouse mammary tumor virus Mtv-17 is involved in Mtv-2-induced tumorigenesis in GR mice.
Virology
218:14-22[CrossRef][Medline].
|
| 7.
|
Golovkina, T. V.,
I. Piazzon,
I. Nepomnaschy,
V. Buggiano,
M. de Olano Vela, and S. R. Ross.
1997.
Generation of a tumorigenic milk-borne mouse mammary tumor virus by recombination between endogenous and exogenous viruses.
J. Virol.
71:3895-3903[Abstract].
|
| 8.
|
Günzburg, W. H.,
F. Heinemann,
S. Wintersperger,
T. Miethke,
H. Wagner,
V. Erfle, and B. Salmons.
1993.
Endogenous superantigen expression controlled by a novel promoter located in the MMTV long terminal repeat.
Nature
354:154-158.
|
| 9.
|
Günzburg, W. H.,
R. M. Saller, and B. Salmons.
1995.
Retroviral vectors directed to predefined cell types for gene therapy.
Biologicals
23:5-12[CrossRef][Medline].
|
| 10.
|
Miller, C. L.,
R. Garner, and V. Paetkau.
1992.
An activation-dependent, T-lymphocyte-specific transcriptional activator in the mouse mammary tumor virus env gene.
Mol. Cell. Biol.
12:3262-3272[Abstract/Free Full Text].
|
| 11.
|
Reuss, F., and J. M. Coffin.
1998.
Mouse mammary tumor virus superantigen expression in B cells is regulated by a central enhancer within the pol gene.
J. Virol.
72:6073-6082[Abstract/Free Full Text].
|
| 12.
|
Salmons, B., and W. H. Günzburg.
1987.
Current perspectives in the biology of mouse mammary tumour virus.
Virus Res.
8:81-102[CrossRef][Medline].
|
| 13.
|
Salmons, B.,
B. Groner,
C.-M. Calberg-Bacq, and H. Ponta.
1985.
Production of mouse mammary tumour virus upon transfection of a recombinant proviral DNA into cultured cells.
Virology
144:101-114[CrossRef][Medline].
|
| 14.
|
Salmons, B.,
S. Wintersperger, and W. H. Günzburg.
1994.
On the generation of endogenous superantigen diversity.
Immunol. Today
15:191-192[CrossRef][Medline].
|
| 15.
|
Sambasivarao, D., and V. Paetkau.
1996.
Interactions of a transcriptional activator in the env gene of the mouse mammary tumor virus with activation-dependent, T cell-specific transacting factors.
J. Biol. Chem.
271:8942-8950[Abstract/Free Full Text].
|
| 16.
|
Wintersperger, S.,
S. Indraccolo,
T. Miethke,
W. H. Günzburg, and B. Salmons.
1994.
A transient assay for gene expression studies in B-lymphocytes and its use for superantigen assays.
BioTechniques
16:882-886[Medline].
|
| 17.
|
Wintersperger, S.,
B. Salmons,
T. Miethke,
V. Erfle,
H. Wagner, and W. H. Günzburg.
1995.
Negative acting factor and superantigen are separable activities encoded by the mouse mammary tumor virus long terminal repeat.
Proc. Natl. Acad. Sci. USA
92:2745-2749[Abstract/Free Full Text].
|
| 18.
|
Zhang, D.-J.,
V. K. Tsiagbe,
C. Huang, and G. J. Thorbecke.
1996.
Control of endogenous mouse mammary tumor virus superantigen expression in SJL lymphomas by a promoter within the env region.
J. Immunol.
157:3510-3517[Abstract].
|
Journal of Virology, March 2000, p. 2900-2902, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Rouault, F., Nejad Asl, S. B., Rungaldier, S., Fuchs, E., Salmons, B., Gunzburg, W. H.
(2007). Promoter Complex in the Central Part of the Mouse Mammary Tumor Virus Long Terminal Repeat. J. Virol.
81: 12572-12581
[Abstract]
[Full Text]